or Try an Advanced Search...

    Technical Analysis for BCDA - BioCardia, Inc.

    Grade Last Price % Change Price Change
    F 2.39 2.58% 0.06
    BCDA closed up 2.58 percent on Friday, November 1, 2024, on 2 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 6
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical BCDA trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Down 3 Days in a Row Weakness 2.58%
    Lower Bollinger Band Touch Weakness 2.58%
    Oversold Stochastic Weakness 2.58%
    Stochastic Reached Oversold Weakness 0.84%
    Oversold Stochastic Weakness 0.84%
    180 Bearish Setup Bearish Swing Setup -1.24%
    Oversold Stochastic Weakness -1.24%
    Older End-of-Day Signals for BCDA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 22 hours ago
    Up 3% about 22 hours ago
    Gap Up Closed about 22 hours ago
    Gap Up Partially Closed about 22 hours ago
    Gapped Up (Partial) about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    BCDA Chart by TradingView
    Basic chart:

    Profile

    BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Biology Bone Stem Cell Cell Therapy Catheter Cardiovascular Disease Heart Failure Vascular Disease Regenerative Medicine Heart Disease Vascular Access Products Aging Associated Diseases Bone Marrow Ischemia Treatment Of Heart Failure

    Is BCDA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 28 BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
    Oct 9 BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
    Sep 18 BioCardia regains compliance with Nasdaq Capital Market
    Sep 18 BioCardia Regains Full Compliance with Nasdaq Listing Requirements
    Sep 15 Wall Street Breakfast: The Week Ahead
    Sep 9 BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
    Sep 4 Peering Into BioCardia's Recent Short Interest
    Aug 30 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
    Aug 30 Why MongoDB Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Aug 29 Dow Jumps Over 100 Points; Nvidia Earnings Top Views
    See more BCDA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 23.25
    52 Week Low 1.9562
    Average Volume 1,038,071
    200-Day Moving Average 4.42
    50-Day Moving Average 2.67
    20-Day Moving Average 2.55
    10-Day Moving Average 2.47
    Average True Range 0.21
    RSI (14) 43.18
    ADX 11.41
    +DI 20.07
    -DI 18.75
    Chandelier Exit (Long, 3 ATRs) 2.27
    Chandelier Exit (Short, 3 ATRs) 2.94
    Upper Bollinger Bands 2.81
    Lower Bollinger Band 2.30
    Percent B (%b) 0.18
    BandWidth 19.88
    MACD Line -0.09
    MACD Signal Line -0.08
    MACD Histogram -0.0188
    Fundamentals Value
    Market Cap 56.45 Million
    Num Shares 23.6 Million
    EPS -0.62
    Price-to-Earnings (P/E) Ratio -3.85
    Price-to-Sales 17.62
    Price-to-Book 10.67
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.54
    Resistance 3 (R3) 2.54 2.49 2.52
    Resistance 2 (R2) 2.49 2.45 2.49 2.51
    Resistance 1 (R1) 2.44 2.42 2.44 2.44 2.50
    Pivot Point 2.38 2.38 2.39 2.39 2.38
    Support 1 (S1) 2.34 2.35 2.34 2.34 2.28
    Support 2 (S2) 2.28 2.32 2.28 2.27
    Support 3 (S3) 2.23 2.28 2.26
    Support 4 (S4) 2.24